Open Innovation Tackles NCDs in Africa
December 9, 2014 Editor
The Devex Impact website reported that to understand more about Africa’s increasing noncommunicable diseases (NCD) threat, we need to bring together the brightest scientific minds to work as a team rather than struggling alone to find answers. No single country in the region has enough researchers with the appropriate mix of skills required to tackle this challenge. GlaxoSmithKline is drawing on its research expertise to help kickstart the discovery of new and better treatments for NCDs. But its approach to tackling these diseases in Africa is turning the usual model of closely guarded research and development on its head with the establishment of the world’s first R&D “Open Lab” for NCDs in sub-Saharan Africa.
Click here to read the full article.
- Prevention and Management of Non-Communicable Disease: The IOC Consensus Statement, Lausanne 2013.
- Strategies to support non-communicable disease interventions
- New fund for young developing world innovators to tackle deadly global health conditions
- Global health: Lifting the burden
- A systematic review of the literature on self-management interventions and discussion of their potential relevance for people living with HIV in sub-Saharan Africa.
- Africa: Q&A – Omotade Akin Aina On Expanding PhDs in Africa
Categories: Open Innovation
Subscribe to our stories
- Device that recycles vaporized water from power plants wins MIT $100K May 28, 2019
- Why Do Foreign Investors’ Attitudes toward Women Matter? May 28, 2019
- When less is more: coordinating innovation in open versus closed source software development May 28, 2019
- Social entrepreneurship: an emerging market perspective, some fresh evidence from Ghana May 28, 2019
- Influence of personal traits on social entrepreneurship intention: an empirical study related to Tunisia May 28, 2019